Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs
Since anticholinergics were firstly used as an antiparkinsonian drug over half a century ago, a lot of antiparkinsonian drugs have been developed and are now on the market. Although levodopa is most effective and still the gold standard therapy for Parkinson’s disease (PD), its side effects of motor complication such as wearing off and dyskinesia limited its use and prompted the development of novel antiparkinsonian drugs. Dopamine agonists are most commonly used drugs among them, but their serious side effects such as sleep attack and impulsive-compulsive disorders are also well-recognized. In this chapter we focus on the common and specific side effects of antiparkinsonian drugs as well as their clinically important drug-drug interactions.
- Cruz MP. Xadago (Safinamide). A monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson’s disease. PT. 2017;42(10):622–624,637.Google Scholar
- Goralski KB, et al. In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport. J Pharmacol Exp Ther. 1999;290(2):496–504.Google Scholar
- Katzenschlager R, et al. Anticholinergics for symptomatic management of Parkinson’s disease (Cochrane Review). Cochrane Database Syst Rev. 2003;(2):CD003735.Google Scholar
- Stowe R, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;16(2):CD006564.Google Scholar